FDA label checked · Novo Nordisk pricing checked · Subscription terms checked · Affiliate disclosure
Sources: FDA prescribing information (2026 label), STEP UP trial (Lancet Diabetes & Endocrinology, 2025), Novo Nordisk official pricing and press releases (March–April 2026)
Wegovy HD vs Wegovy: Should You Switch After 2.4 mg?
The verdict
Most people should stay on regular Wegovy. The 7.2 mg dose is the better choice only if you’re an adult using Wegovy for weight loss, you’ve tolerated 2.4 mg for at least four weeks, and you still need more weight reduction. In the STEP UP trial — the only head-to-head comparison of both doses — HD added roughly 3.3 extra percentage points of weight loss over standard Wegovy (18.8% vs 15.5%). But it costs $50 more per month ($399 vs $349 self-pay), isn’t on the cheaper subscription program yet, and raises the risk of dysesthesia (altered skin sensation) from 6% to 22%.
The most compelling HD number: 31.2% of HD patients lost 25% or more of their body weight — roughly double the 15.3% on standard Wegovy. If you’ve plateaued and still have significant weight to lose, that’s a real signal.
| Standard Wegovy (2.4 mg) | Wegovy HD (7.2 mg) | |
|---|---|---|
| Best for | Most adults; also teens 12+, CV risk, MASH | Adults who tolerated 2.4 mg ≥4 weeks and need more loss |
| Avg. weight loss (adults, no diabetes) | 15.5% (all patients) | 18.8% (all patients) |
| Reached ≥25% weight loss | 15.3% | 31.2% |
| Main tradeoff | Fewer side effects, cheaper, on subscription | More weight loss, but higher cost + dysesthesia |
| Self-pay price | $349/mo ($249/mo with 12-mo subscription) | $399/mo (not yet on subscription) |
STEP UP trial treatment regimen estimand (all randomized patients). Pricing: NovoCare / Novo Nordisk, April 2026.
Get a personalized action plan — no commitment, no cost
Jump to: What we verified · Is HD actually better? · Full decision grid · Who should switch · Weight loss data · Side effects · Pricing · How to switch · Where to get it · FAQ
What We Actually Verified for This Page
We don’t ask you to trust us. We ask you to check our work. Every number on this page comes from one of four primary sources:
Clinical data
The STEP UP trial — 72-week, randomized, double-blinded, Phase 3b, comparing semaglutide 7.2 mg vs 2.4 mg vs placebo in 1,407 adults with obesity and no diabetes. Published in Lancet Diabetes & Endocrinology, 2025, Vol 13, Issue 11. The only trial comparing both doses head-to-head in the same patient population.
Side effects, eligibility, safety warnings
Current FDA prescribing information for Wegovy, updated to include the 7.2 mg dose (2026 label, accessdata.fda.gov).
Pricing
NovoCare official pricing page and Novo Nordisk press releases — April 7, 2026 nationwide launch announcement for HD pricing ($399/mo), and the March 31, 2026 subscription program announcement confirming HD is not yet included.
Provider availability
Novo Nordisk's public statements about distribution channels. Where we couldn't verify a specific provider's HD availability from their public-facing page, we marked it.
The RX Index has no financial relationship with Novo Nordisk. We earn affiliate commissions from some providers listed on this page, which we disclose where relevant. This does not affect our recommendations — the data comes first.
Is Wegovy HD Actually Better Than Regular Wegovy?
Not for most people. Regular Wegovy remains the right default for the majority of patients. Wegovy HD is a narrower, later-stage option designed for a specific subgroup: adults who’ve already been on 2.4 mg, tolerated it well, and still have clinically meaningful weight left to lose.
HD is not “new and improved Wegovy.” It’s a step-up option that didn’t exist before March 2026. Standard Wegovy hasn’t gotten worse because HD launched. If 2.4 mg is getting you where you need to go, the arrival of a higher dose changes nothing about your treatment.
The Honest Tradeoff
We’ll say this plainly because most comparison pages won’t: Wegovy HD does NOT make sense if cost is your main concern or if 2.4 mg already pushes your side-effect tolerance. In those cases, standard Wegovy is the better drug for you.
But here’s why HD exists: a meaningful share of patients on 2.4 mg plateau before reaching a healthy weight. For that group, the previous options were limited — switch drug classes, consider bariatric surgery, or accept the plateau. HD gives them one more step within semaglutide before making a bigger change. The STEP UP data backs that up.
Standard Wegovy wins when:
- ✓Still losing weight on 2.4 mg (or still titrating)
- ✓You're a teenager — HD is adults-only
- ✓Using Wegovy for CV risk or MASH
- ✓Price-sensitive and self-pay
- ✓Side effects on 2.4 mg were already rough
Wegovy HD wins when:
- ✓Plateaued on 2.4 mg, BMI still well above goal
- ✓Tolerated full titration with minimal GI issues
- ✓Want strongest available semaglutide injection
- ✓Cost premium is manageable
- ✓Need highest odds of ≥25% weight loss (31.2% vs 15.3%)
The RX Index Wegovy HD Switch Decision Grid
All weight-loss figures below use the treatment regimen estimand — meaning they include all randomized patients regardless of whether they stayed on treatment. This is the more conservative, real-world-relevant number.
| Decision Point | Standard Wegovy (2.4 mg) | Wegovy HD (7.2 mg) | What It Means for You |
|---|---|---|---|
| Who it's for | Standard maintenance for adults and teens 12+; also dosed for CV-risk reduction and MASH in adults | Step-up only for adults using Wegovy for weight loss who tolerated 2.4 mg ≥4 weeks | HD is not "default Wegovy." It's a narrower, later-stage option. |
| Earliest label-consistent path to HD | Start at 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg (16-week escalation) | 16 weeks of titration + at least 4 weeks tolerating 2.4 mg = week 20 at the earliest | You cannot shortcut the timeline. |
| Avg. weight loss — adults with obesity, no diabetes | 15.5% (all patients) / 17.5% (completers) | 18.8% (all patients) / 20.7% (completers) | Real extra benefit: +3.3 percentage points. Meaningful, not transformative. |
| Avg. weight loss — adults with obesity and T2D | 10.4% | 13.2% | Extra benefit exists with diabetes, but smaller: +2.8 points. |
| % achieving ≥20% loss (no diabetes) | 32.3% | 45.5% | About 13 more people per 100 hit the 20% mark on HD. |
| % achieving ≥25% loss (no diabetes) | 15.3% | 31.2% | HD's most persuasive number: roughly double the chance of hitting 25% loss. |
| GI side effects (any) | ~61% | ~71% | More frequent — but 10 extra people per 100, not a completely different experience. |
| Dysesthesia (altered skin sensation) | 6% | 22% | The standout tradeoff: +16 percentage points. |
| Discontinued due to side effects | 5% | 5% | Identical. More side effects does NOT mean more people had to quit. |
| Self-pay cost | $349/mo ($249/mo with 12-mo subscription) | $399/mo (subscription not yet available) | HD costs $50–$150/mo more depending on subscription eligibility. |
| Novo subscription included? | Yes — 3/6/12-month plans through Ro, LifeMD, WeightWatchers | Not yet. Novo stated it "will be added at a later date." | For self-pay users, standard Wegovy has the better cost math right now. |
| Pen format (U.S.) | Single-dose pens: 0.25, 0.5, 1.0, 1.7, 2.4 mg | Dedicated single-dose pen: 7.2 mg/0.75 mL | One pen, one shot, once a week. HD is NOT three injections. |
| Pill option? | Yes (Wegovy pill, oral semaglutide 25 mg daily) | No | No HD pill path exists. |
| FDA-approved indications | Weight loss (adults + teens 12+), CV risk reduction, MASH | Weight loss (adults only) | Standard Wegovy has a broader label. |
Sources: STEP UP trial treatment regimen estimand (Lancet, 2025); STEP UP T2D trial (Lancet, 2025); FDA prescribing information (2026); Novo Nordisk press releases (March 19, March 31, April 7, 2026); NovoCare pricing page.
Quick Myth-Bust: Is Wegovy HD Three Shots?
Is Wegovy HD a New Drug?
No. Same active ingredient (semaglutide), same manufacturer (Novo Nordisk), same GLP-1 mechanism. The difference is the dose: 7.2 mg per injection vs the standard maintenance dose of 2.4 mg — 3× higher by concentration, delivered in a single pen designed for the larger volume. Think of it as a dose extension, not a new medication.
Who Should Switch from Wegovy 2.4 mg to Wegovy HD?
The FDA label defines the HD candidate narrowly: an adult using Wegovy for weight reduction who has tolerated the 2.4 mg dose for at least four weeks and for whom additional weight loss is clinically indicated. That language matters — “clinically indicated” means your prescriber determines you need more weight loss based on your health picture, not just that you’d prefer to lose more.
✅ Best fit: Plateaued on 2.4 mg, still well above goal
You’ve been on 2.4 mg for months. The first 10–15% came off, then the scale stopped moving. Your BMI is still well above your clinical goal. GI side effects have faded to background noise. The “food noise” is creeping back. The STEP UP trial showed that escalating to 7.2 mg added meaningful incremental loss — particularly at the high end, where about one-third of patients hit the ≥25% weight loss threshold.
❌ Not a fit: You haven’t started Wegovy yet
You cannot start on Wegovy HD. There is no shortcut. The label requires a full dose escalation from 0.25 mg through 2.4 mg before HD is even on the table. Start the standard path, see how your body responds, and revisit the HD question if you’re still short of your goal after reaching 2.4 mg.
New to Wegovy entirely? Best Telehealth for Wegovy: Verified Options →
❌ Not a fit: Side effects on 2.4 mg were already rough
If you struggled through the titration — persistent nausea at every dose step, vomiting that didn’t resolve, GI distress that affected your daily life — tripling the dose is unlikely to improve that picture. The STEP UP data showed GI side effects in 71% of HD patients vs 61% at 2.4 mg. And the dysesthesia issue (22% vs 6%) is an entirely new variable at the higher dose.
❌ Not a fit: Budget-first self-pay patients
Standard Wegovy with a 12-month subscription through Novo’s program is $249/month. Wegovy HD is $399/month and is NOT yet on the subscription program. That’s a $150/month gap — $1,800/year — for 3.3 extra percentage points of weight loss. At the subscription rate, standard Wegovy is significantly more cost-effective per point of weight loss.
The Earliest You Can Qualify
We calculated the fastest label-consistent path to HD based on the standard titration schedule:
| Weeks | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 0.25 mg | Starting dose |
| Weeks 5–8 | 0.5 mg | First increase |
| Weeks 9–12 | 1.0 mg | Second increase |
| Weeks 13–16 | 1.7 mg | Third increase |
| Weeks 17–20+ | 2.4 mg | Maintenance — minimum 4 weeks required before stepping up |
| Week 20+ (earliest) | 7.2 mg (HD) | Only if tolerated 2.4 mg ≥4 weeks and additional weight loss is clinically indicated |
Get started for $39, then as low as $74/mo with annual plan. Insurance concierge included.
How Much More Weight Can You Actually Lose on Wegovy HD?
In the STEP UP trial, adults with obesity and no diabetes lost an average of 18.8% of their body weight on Wegovy HD vs 15.5% on standard Wegovy (all randomized patients, treatment regimen estimand). Among those who stayed on treatment the entire 72 weeks, the numbers were 20.7% vs 17.5%. The additional weight loss from HD is real — roughly 3.3 extra percentage points — but it’s an increment, not a transformation.
What 3.3 Extra Percentage Points Looks Like in Pounds
| Starting weight | Loss at 15.5% (Standard) | Loss at 18.8% (HD) | Extra lbs from HD |
|---|---|---|---|
| 200 lbs | 31 lbs | 37.6 lbs | +6.6 lbs |
| 225 lbs | 34.9 lbs | 42.3 lbs | +7.4 lbs |
| 250 lbs | 38.8 lbs | 47.0 lbs | +8.2 lbs |
| 275 lbs | 42.6 lbs | 51.7 lbs | +9.1 lbs |
| 300 lbs | 46.5 lbs | 56.4 lbs | +9.9 lbs |
For someone starting at 250 lbs, that’s roughly 8 extra pounds over 72 weeks. Meaningful for some — not the 30-pound dramatic difference some headlines imply.
Where HD Really Shines: The High-Loss Thresholds
The average tells one story. The threshold data tells a more compelling one. In STEP UP, 45.5% of HD patients lost 20% or more of their body weight, compared to 32.3% on standard Wegovy. And 31.2% lost 25% or more — roughly double the 15.3% who hit that mark at 2.4 mg.
If you need to lose a quarter of your body weight or more to reach a healthy range, your odds of getting there are roughly twice as high on HD vs standard Wegovy. At 2.4 mg, about 1 in 7 patients reaches 25% loss. At 7.2 mg, it’s about 1 in 3.
What Gets Worse at 7.2 mg?
The central tradeoff of Wegovy HD is side effects. The FDA label shows nausea, vomiting, and altered skin sensations more often at 7.2 mg, with dysesthesia reported in 22% of HD patients vs 6% at 2.4 mg and 0.3% on placebo. Despite the increase, the rate of people who permanently stopped treatment because of adverse reactions was identical: 5% in both groups.
Dysesthesia: The One Side Effect You Need to Understand
Dysesthesia (pronounced dis-es-THEE-zhuh) is an altered sensation on the skin. The FDA groups it with related sensations including paresthesia (tingling), hyperesthesia (increased sensitivity), and skin burning sensation. Patients have described their skin feeling unusually sensitive to touch, clothing, or temperature.
| Side effect | Wegovy HD (7.2 mg) | Standard Wegovy (2.4 mg) | Placebo |
|---|---|---|---|
| Dysesthesia (any altered skin sensation) | 22% | 6% | 0.3% |
| Nausea | ~39% | ~35% | lower |
| Vomiting | ~22% | ~16% | lower |
| GI side effects (any) | ~71% | ~61% | lower |
| Discontinued due to adverse reactions | 5% | 5% | 2% |
Source: STEP UP trial (Lancet, 2025); FDA prescribing information (2026 label).
What we know about how it resolves: The FDA notes that dysesthesia at the 7.2 mg dose was generally reported as mild to moderate. The overall rate of treatment discontinuation due to any adverse event was the same (5%) for both groups, suggesting that for most patients, the side effect was manageable enough to continue treatment. Published case literature describes it as typically dose-dependent and often resolving spontaneously or with dose adjustment.
GI Side Effects: More Frequent, Not Dramatically Worse
About 71% of HD patients reported any GI side effect vs 61% on standard Wegovy. The GI escalation is a single step (2.4 → 7.2 mg), not a full re-titration from scratch. If your body already adapted to semaglutide through the 16-week dose escalation, the jump to HD is building on an existing tolerance — not starting over. That said, have a plan with your prescriber for managing nausea if you step up.
Hair Loss: Now Formally Listed
Hair loss appears among the common adverse reactions for Wegovy HD. This is not unique to HD or even to semaglutide — temporary hair shedding (telogen effluvium) is a known consequence of rapid weight loss from any cause, including bariatric surgery. The driver is typically caloric deficit and nutritional status, not the medication itself. If you’re stepping up to HD, protein intake matters more than ever.
Important Safety Information: What Both Doses Share
Both standard Wegovy and Wegovy HD carry the same foundational safety warnings regardless of which dose you’re on:
Boxed warning (strongest FDA safety warning)
In rodent studies, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy causes medullary thyroid carcinoma (MTC) in humans. Wegovy is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.
Pancreatitis
Acute pancreatitis has been reported with GLP-1 receptor agonists. Discontinue promptly if pancreatitis is suspected and do not restart if confirmed.
Diabetic retinopathy
In patients with T2D, worsening retinopathy has been associated with rapid improvement in glucose control. Monitor for changes in vision.
Gallbladder disease
Gallstones and inflammation of the gallbladder have been reported. Report persistent severe abdominal pain.
Suicidal ideation
Monitor for new or worsening depression, suicidal thoughts, or behavioral changes.
This is an editorial summary, not a substitute for the full prescribing information. Read the complete FDA label and discuss all risks with your prescriber before starting or changing dose.
How Wegovy HD Is Delivered: One Pen, One Shot, Once a Week
Wegovy HD is delivered via a dedicated single-dose pen containing 7.2 mg/0.75 mL of semaglutide. One pen, one injection, once a week — the same schedule as every other Wegovy dose. There’s no change to how you inject or how often.
The HD pen is a distinct physical device from the standard dose pens. Your pharmacy will need to order it specifically under the Wegovy HD NDC. As of April 7, 2026, Novo Nordisk confirmed HD is available at 70,000+ U.S. retail pharmacies and through NovoCare Pharmacy for home delivery.
Wegovy HD vs Wegovy Pricing: The Complete 2026 Picture
The self-pay gap is $50/month. The subscription gap is $150/month. The insurance story is more complicated — and more important.
| Plan type | Standard Wegovy | Wegovy HD |
|---|---|---|
| Self-pay, no subscription | $349/mo | $399/mo |
| 3-month subscription | $329/mo | Not available |
| 6-month subscription | $299/mo | Not available |
| 12-month subscription | $249/mo ★ | Not available |
| Commercial insurance + savings card | As low as $25/mo | As low as $25/mo |
| Medicare GLP-1 Bridge (July 2026) | $50/mo | $50/mo (confirmed by CMS) |
| List price (before discounts) | $1,349.02/mo | $1,349.02/mo |
★ Subscription available through Ro, WeightWatchers, LifeMD; Hims & Hers and Sesame expected soon. Sources: Novo Nordisk press releases March 31, April 7, 2026; NovoCare pricing page; CMS Medicare GLP-1 Bridge FAQ (April 6, 2026).
The Subscription Blind Spot Nobody Is Framing
Insurance and Savings Cards
Wegovy HD is expected to fall under the same formulary tier as standard Wegovy for most commercial plans. However, HD launched April 7, 2026 — very recently — and coverage databases may not be updated yet. We recommend:
- Call your insurance pharmacy line and ask specifically about Wegovy HD 7.2 mg (NDC may differ from standard Wegovy)
- If your plan covers Wegovy, ask whether HD requires a separate prior authorization
- Confirm the Novo Nordisk savings card (WegovyTerms.com) applies to HD specifically
Medicare Coverage
The Medicare GLP-1 Bridge program launching July 1, 2026 covers all formulations of Wegovy — including HD — at a flat $50/month copay for eligible beneficiaries. CMS confirmed this in an April 2026 update to the Bridge FAQ, listing Wegovy HD’s NDC among the covered products. For the full Medicare picture, see our Medicare GLP-1 Bridge guide →
Get started for $39, then as low as $74/mo annual plan. Ro handles prior authorizations and appeals.
What If You Have T2D, Heart Risk, MASH, or Are Under 18?
Type 2 Diabetes
HD works in T2D, but calibrate your expectations. The STEP UP T2D trial showed 13.2% average weight loss on 7.2 mg vs 10.4% on 2.4 mg — a 2.8-point gap, smaller than the 3.3-point gap in non-diabetic patients. The benefit is real. Discuss with your prescriber whether the incremental loss justifies the incremental cost and side-effect exposure in your specific metabolic context.
Cardiovascular Risk Reduction
Wegovy (standard dose) has uniquely strong cardiovascular data: the SELECT trial — 17,604 patients, 39+ months — showed a 20% reduction in major adverse cardiovascular events. The 7.2 mg step-up language in the current label is specifically within the weight-reduction section. The CV-risk maintenance dosing is laid out separately at 2.4 mg (or 1.7 mg if 2.4 mg isn't tolerated). HD was not specifically studied or approved for CV-risk-reduction dosing. Your cardiologist or prescriber should make this call.
MASH (Metabolic Dysfunction-Associated Steatohepatitis)
Wegovy injection received accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis. The maintenance dose for this indication is 2.4 mg. HD is not specifically indicated for MASH. If you're using Wegovy for MASH, talk to your hepatologist or gastroenterologist about whether a dose change is appropriate.
Teens 12–17
Wegovy HD is not for adolescents. This is a hard stop, not a gray area. Standard Wegovy injection is approved for teens 12 and older with obesity. The 7.2 mg dose is labeled for adults only.
How Do You Actually Switch from 2.4 mg to Wegovy HD?
For the right adult patient, the switch is straightforward. The label says patients who tolerate the 2.4 mg dose for at least four weeks and still need additional weight reduction may increase to 7.2 mg once weekly. There is no re-titration — you go directly from 2.4 mg to 7.2 mg in a single step.
Practical Steps
- Confirm you’ve been on 2.4 mg for at least 4 weeks — this is a label requirement, not a suggestion
- Talk to your prescriber (in-person or telehealth) about whether HD is clinically indicated. Bring data: weight-loss trajectory, current BMI, how you’ve tolerated side effects
- Get a new prescription for Wegovy HD (semaglutide injection 7.2 mg) — this is a separate product; your pharmacy needs to order it specifically
- Check pharmacy stock — HD launched April 7, 2026 and inventory may still be building at some locations
- Verify insurance or savings — if you have coverage for standard Wegovy, confirm it extends to HD; if self-pay, budget for $399/month until the subscription program includes HD
What to Ask Your Prescriber
- “Based on my weight-loss trajectory on 2.4 mg, is stepping up to 7.2 mg likely to produce a clinically meaningful additional benefit for me?”
- “Given my side-effect history, what should I watch for at the higher dose — especially the altered skin sensation that’s been flagged?”
- “If I don’t tolerate 7.2 mg, can I step back to 2.4 mg?”
- “Is there a reason to consider switching drug classes instead of escalating within semaglutide?”
Where Can You Actually Get Brand-Name Wegovy or Wegovy HD?
As of April 7, 2026, Novo Nordisk confirmed Wegovy HD is available nationwide through 70,000+ U.S. retail pharmacies, NovoCare Pharmacy (with home delivery), and “select telehealth providers.”
| Channel | Standard Wegovy confirmed? | HD confirmed? | Insurance support? | Date checked |
|---|---|---|---|---|
| Retail pharmacies (nationwide) | ✅ Yes | ✅ Yes (Novo launch announcement) | Depends on plan | April 2026 |
| NovoCare Pharmacy (home delivery) | ✅ Yes | ✅ Yes (Novo launch announcement) | Savings card eligible | April 2026 |
| Ro | ✅ Yes (NovoCare recognized provider) | ⚠️ Not confirmed from Ro's public pages | ✅ Insurance concierge included | April 2026 |
| WeightWatchers | ✅ Yes | ⚠️ Not confirmed | Varies | April 2026 |
| LifeMD | ✅ Yes | ⚠️ Not confirmed | Varies | April 2026 |
⚠️ = standard Wegovy confirmed; HD-specific availability not yet verified from provider’s public pages as of April 12, 2026. We will update as we verify each channel.
What we can confirm about Ro: they prescribe standard brand-name Wegovy (injection and pill) through NovoCare Pharmacy, provide insurance concierge support for prior authorizations and appeals, and are listed on Novo Nordisk’s NovoCare recognized-provider page. Whether HD is accessible through Ro is not yet confirmed from their public-facing pages.
“Having the team at Ro help me navigate insurance was a huge relief.” — Colleen, Ro member
“With Ro, you actually get to talk to actual human beings. It just makes you feel supported.” — Gray, Ro member
Disclosure: Ro states these members were paid for their testimonials. The RX Index earns affiliate commissions from Ro.
Whether you’re exploring HD or staying on standard Wegovy, the real blocker for most people is insurance coverage. Ro’s concierge team handles prior authorizations, follows up on denials, and files appeals — so you don’t have to.
Get started for $39, then as low as $74/mo annual plan. Medication cost is separate from Ro's membership.
Is Wegovy HD the Same as Compounded Semaglutide 7.2 mg?
No. And this distinction matters more at the higher dose. Wegovy HD is an FDA-approved product manufactured by Novo Nordisk with specific quality controls, a defined pen-injector delivery system, and clinical trial data from 1,407 patients supporting its expected outcomes and risks.
Compounded semaglutide products are prepared by compounding pharmacies, are not FDA-approved as finished products, and do not go through the same manufacturing, quality, or testing standards. The FDA has issued multiple warnings about compounded GLP-1 products, including concerns about incorrect potency, contamination, and misleading marketing.
How We Verified This Page
Primary sources used:
- FDA prescribing information for Wegovy (2026 updated label including 7.2 mg), accessed via accessdata.fda.gov
- STEP UP trial: Wharton S et al. “Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP).” Lancet Diabetes & Endocrinology. 2025;13(11):949–963
- STEP UP T2D trial: Lingvay I et al. “Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D).” Lancet Diabetes & Endocrinology. 2025;13(11):935–948
- Novo Nordisk press release: “FDA approves Novo Nordisk’s new Wegovy HD injection” (March 19, 2026)
- Novo Nordisk press release: “Novo Nordisk’s Wegovy HD available now nationwide” (April 7, 2026)
- Novo Nordisk press release: “Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy” (March 31, 2026)
- NovoCare official pricing page: novocare.com/patient/medicines/wegovy.html
- CMS Medicare GLP-1 Bridge FAQ (updated April 6, 2026): cms.gov/medicare
Last verified: April 12, 2026 · Next audit: May 12, 2026
Related guides:
Frequently Asked Questions: Wegovy HD vs Wegovy
Is Wegovy HD better than regular Wegovy?
Not for most people. Wegovy HD delivers about 3.3 extra percentage points of weight loss over standard Wegovy in adults with obesity and no diabetes, but costs more, isn't on the subscription program, and raises dysesthesia risk from 6% to 22%. It's the better choice specifically for adults who've tolerated 2.4 mg, still need significant weight loss, and accept the tradeoffs.
Can you start on Wegovy HD without taking Wegovy first?
No. The FDA label requires tolerating Wegovy 2.4 mg for at least 4 weeks before stepping up to 7.2 mg. The earliest label-consistent path to HD is approximately week 20 of treatment.
Is Wegovy HD a single pen or three injections?
In the U.S., Wegovy HD is a dedicated single-dose pen containing 7.2 mg/0.75 mL of semaglutide. One pen, one injection, once a week. The three-injection approach was used in the U.K. before the single-dose pen was available and does not apply to the current U.S. product.
How much more weight can you lose on Wegovy HD?
In the STEP UP trial (adults with obesity, no diabetes), HD patients lost an average of 18.8% of body weight vs 15.5% for standard Wegovy (all randomized patients). 31.2% of HD patients lost 25% or more of body weight, roughly double the 15.3% who hit that mark on the standard dose.
Does Wegovy HD have worse side effects?
GI side effects are somewhat more frequent (71% vs 61%), and dysesthesia (altered skin sensation) is significantly more common (22% vs 6%). However, the rate of patients who permanently discontinued treatment due to side effects was identical at 5% for both doses.
Is Wegovy HD covered by insurance?
Novo Nordisk confirmed that commercially insured patients may pay as little as $25 per month for Wegovy HD with the savings card. Verify directly with your insurance, as coverage databases may not be fully updated yet for this recently launched product.
Does the Medicare GLP-1 Bridge cover Wegovy HD?
Yes. CMS confirmed in April 2026 that all formulations of Wegovy — including HD — are included in the Medicare GLP-1 Bridge starting July 1, 2026, at a $50 per month copay for eligible beneficiaries.
Is Wegovy HD included in the Novo subscription program?
Not yet. Novo Nordisk's multi-month subscription program covers standard Wegovy pen doses — dropping self-pay cost to $249/mo with a 12-month commitment. Wegovy HD will be added at a later date per Novo Nordisk.
Can teens take Wegovy HD?
No. Wegovy HD is approved for adults only. Standard Wegovy injection is approved for adolescents aged 12 and older with obesity.
Is Wegovy HD the same as compounded semaglutide?
No. Wegovy HD is an FDA-approved product with specific quality controls and clinical trial data from 1,407 patients. Compounded semaglutide products are not FDA-approved and do not meet the same manufacturing or testing standards.
What should I ask my prescriber before switching to Wegovy HD?
Ask whether the additional weight loss justifies the cost and side-effect tradeoff based on your trajectory on 2.4 mg, whether the dysesthesia risk is a concern given your side-effect history, and whether staying on standard Wegovy or switching drug classes might be more appropriate.
Still Not Sure Which GLP-1 Program Is Right for You?
If you’ve read this far and the answer is still murky — maybe the cost math doesn’t work for HD, or you’re wondering whether a different medication fits better, or you haven’t started Wegovy yet — take our free 60-second matching quiz. It asks about your situation (not just your weight), routes you to the most relevant next step, and gives you a personalized action plan. No cost, no commitment.
→ Take the Free 60-Second GLP-1 Matching QuizThe RX Index is an independent comparison resource for GLP-1 telehealth providers. This page is updated monthly. All pricing, availability, and clinical claims were verified April 12, 2026 using primary sources listed in the verification section. This content is for informational purposes only and does not constitute medical advice. Wegovy and Wegovy HD are prescription treatments requiring evaluation by a licensed healthcare provider. Last verified: April 12, 2026.